ArticleProceedings of the National Academy of Sciences of the United States of America1995
A mutant p53 antagonizes the deregulated c-myc-mediated enhancement of apoptosis and decrease in leukemogenicity.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 42 citations in OpenAlex.
- Acquisition of Letrozole Resistance Through Activation of the p38/MAPK Signaling Cascade.Anticancer research · 2021Article
- Cancer Stemness: p53 at the Wheel.Frontiers in oncology · 2020Review
- Cyclopentenyl cytosine induces senescence in breast cancer cells through the nucleolar stress response and activation of p53.Molecular pharmacology · 2011Article
- Mutant p53 gain-of-function in cancer.Cold Spring Harbor perspectives in biology · 2010Review
- Mutant p53 mediates survival of breast cancer cells.British journal of cancer · 2009Article
- The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.Nature structural & molecular biology · 2009Article
- Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53.Oncogene · 2006Article
- Induction in myeloid leukemic cells of genes that are expressed in different normal tissues.Proceedings of the National Academy of Sciences of the United States of America · 2004Article
- Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants.Oncogene · 2003Article
- Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil.Oncogene · 2002Article
- Review
- Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis.The EMBO journal · 2001Article
- Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1.Proceedings of the National Academy of Sciences of the United States of America · 2001Article
- Caspases and mitochondria in c-Myc-induced apoptosis: identification of ATM as a new target of caspases.Oncogene · 2000Article
- c-Myc antagonizes the effect of p53 on apoptosis and p21WAF1 transactivation in K562 leukemia cells.Oncogene · 2000Article
- Sensitivity to myc-induced apoptosis is retained in spontaneous and transplanted lymphomas of CD2-mycER mice.Oncogene · 2000Article
- Article
- Mechanisms of apoptosis by c-Myc.Oncogene · 1999Review
- Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy.Oncogene · 1999Article
- p53 and brain tumors: from gene mutations to gene therapy.Brain pathology (Zurich, Switzerland) · 1998Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myeloid leukemic M1 cells that do not express p53 and transfected M1 clones that constitutively express the [Val135]p53 mutant or deregulated c-myc or coexpressing both genes grew autonomously in culture with a similar growth rate and cloning efficiency. Expression of deregulated c-myc in M1 leukemic cells enhanced susceptibility to induction of apoptotic cell death and resulted in a reduced leukemogenicity when injected into isologous mice. Expression of the [Val135]p53 mutant did not change cell susceptibility to induction of apoptosis or leukemogenicity, but expression of this mutant p53 suppressed the effects of deregulated c-myc on these properties. The results indicate that the [Val135]p53 mutant can show a gain of function for susceptibility to apoptosis and leukemogenicity in leukemic cells with deregulated c-myc and, thus, enhance tumor development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.